• Search History (Register)
  • MeSH Browser
  • [Clear]
    • English
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [16493 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     National Institute for Health and Care Excellence (NICE) Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 811
2022     NIHR Health Technology Assessment programme REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022     WorkSafeBC Convergence insufficiency and COVID-19 infection
2022     National Institute for Health and Care Excellence (NICE) Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812
2022     Malaysian Health Technology Assessment (MaHTAS) First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022     WorkSafeBC Lose-dose naltrexone as treatment for post-COVID conditions
2022     National Institute for Health and Care Excellence (NICE) Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022     Scottish Health Technologies Group (SHTG) vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022     National Institute for Health and Care Excellence (NICE) Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022     National Institute for Health and Care Excellence (NICE) Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022     NIHR Health Technology Assessment programme A proportionate, universal parenting programme to enhance social-emotional well-being in infants and toddlers in England: the E-SEE Steps RCT
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022     National Institute for Health and Care Excellence (NICE) Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022     National Institute for Health and Care Excellence (NICE) Setmelanotide for treating obesity caused by LEPR or POMC deficiency. NICE highly specialised technologies guidance 21
2022     NIHR Health Technology Assessment programme Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022     Agency for Care Effectiveness (ACE) Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022     National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022     National Institute for Health and Care Excellence (NICE) Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over. NICE highly specialised technologies guidance 20
2022     NIHR Health Technology Assessment programme Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022     Agency for Care Effectiveness (ACE) Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022     National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma. NICE technology appraisal guidance 818
2022     National Institute for Health and Care Excellence (NICE) Elosulfase alfa for treating mucopolysaccharidosis type 4A. NICE highly specialised technologies guidance 19
2022     Agency for Care Effectiveness (ACE) Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022     National Institute for Health and Care Excellence (NICE) Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies. NICE technology appraisal guidance 819
2022     National Institute for Health and Care Excellence (NICE) Atidarsagene autotemcel for treating metachromatic leukodystrophy. NICE highly specialised technologies guidance 18
2022     Agency for Care Effectiveness (ACE) The PrecivityAD test for the prognosis of Alzheimer's disease
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022     National Institute for Health and Care Excellence (NICE) Brolucizumab for treating diabetic macular oedema. NICE technology appraisal guidance 820
2022     National Institute for Health and Care Excellence (NICE) KardiaMobile for detecting atrial fibrillation. NICE medical technologies guidance 64
2022     National Institute for Health and Care Excellence (NICE) Odevixibat for treating progressive familial intrahepatic cholestasis. NICE highly specialised technologies guidance 17
2022     Agency for Care Effectiveness (ACE) Artificial intelligence and its clinical applications
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022     National Institute for Health and Care Excellence (NICE) Avalglucosidase alfa for treating Pompe disease. NICE technology appraisal guidance 821
2022     Agency for Care Effectiveness (ACE) 3D printing and its clinical applications
2022     National Institute for Health and Care Excellence (NICE) Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal). NICE technology appraisal guidance 822
2022     Agency for Care Effectiveness (ACE) Overview of clinical applications of telemedicine
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022     National Institute for Health and Care Excellence (NICE) Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer. NICE technology appraisal guidance 823
2022     National Institute for Health and Care Excellence (NICE) Memokath 051 Ureter stent for ureteric obstruction. NICE medical technologies guidance 75
2022     Agency for Care Effectiveness (ACE) Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022     National Institute for Health and Care Excellence (NICE) Dexamethasone intravitreal implant for treating diabetic macular oedema. NICE technology appraisal guidance 824
2022     National Institute for Health and Care Excellence (NICE) Optilume for treating recurrent bulbar urethral strictures. NICE medical technologies guidance 73
2022     NIHR Health Services and Delivery Research programme Complex speech-language therapy interventions for stroke-related aphasia: the RELEASE study incorporating a systematic review and individual participant data network meta-analysis
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2022     Agency for Healthcare Research and Quality (AHRQ) Diagnostic errors in the emergency department: a systematic review
2022     National Institute for Health and Care Excellence (NICE) Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. NICE technology appraisal guidance 825
2022     National Institute for Health and Care Excellence (NICE) GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technologies guidance 74
2022     Scottish Health Technologies Group (SHTG) The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022     Center for Drug Evaluation (CDE) Patient involvement in the health technology assessment process in Taiwan
2022     National Institute for Health and Care Excellence (NICE) Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal). NICE technology appraisal guidance 826
2022     National Institute for Health and Care Excellence (NICE) Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer. NICE medical technologies guidance 72
2022     Agency for Care Effectiveness (ACE) Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022     Scottish Health Technologies Group (SHTG) A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2022     National Institute for Health and Care Excellence (NICE) Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy. NICE technology appraisal guidance 827
2022     NIHR Health Technology Assessment programme The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2022     National Institute for Health and Care Excellence (NICE) Ozanimod for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 828
2022     National Institute for Health and Care Excellence (NICE) Faecal microbiota transplant for recurrent Clostridioides difficile infection. NICE medical technologies guidance 71
2022     NIHR Health Technology Assessment programme Transfer of thawed frozen embryo versus fresh embryo to improve the healthy baby rate in women undergoing IVF: the E-Freeze RCT
2022     Agency for Care Effectiveness (ACE) Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022     National Institute for Health and Care Excellence (NICE) Upadacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 829
2022     Health Information and Quality Authority (HIQA) Clinical and cost-effectiveness of healthcare-associated infection interventions: a systematic review
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of renal cell carcinoma. NICE technology appraisal guidance 830
2022     Health Information and Quality Authority (HIQA) Budget impact analysis – National Clinical Guideline: Infection prevention and control
2022     National Institute for Health and Care Excellence (NICE) Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids. NICE technology appraisal guidance 832
2022     NIHR Health Technology Assessment programme Dynamic contrast-enhanced CT compared with positron emission tomography CT to characterise solitary pulmonary nodules: the SPUtNIk diagnostic accuracy study and economic modelling
2022     Agency for Healthcare Research and Quality (AHRQ) Evaluation of mental health mobile applications
2022     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 833
2022     National Institute for Health and Care Excellence (NICE) SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal). NICE technology appraisal guidance 834
2022     Malaysian Health Technology Assessment (MaHTAS) Transcutaneous oxygen pressure monitoring (TcPO2)
2022     Agency for Healthcare Research and Quality (AHRQ) Improving rural health through telehealth-guided provider-to-provider communication
2022     National Institute for Health and Care Excellence (NICE) Fostamatinib for treating refractory chronic immune thrombocytopenia. NICE technology appraisal guidance 835
2022     Penn Medicine Center for Evidence-based Practice (CEP) VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022     Malaysian Health Technology Assessment (MaHTAS) Sublingual immunotherapy (SLIT) for atopy (allergic rhinitis, eczema and asthma)
2022     Agency for Healthcare Research and Quality (AHRQ) Infection prevention and control for the emergency medical services and 911 workforce
2022     National Institute for Health and Care Excellence (NICE) Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 836
2022     National Institute for Health and Care Excellence (NICE) Sleepio to treat insomnia and insomnia symptoms. NICE medical technologies guidance 70
2022     Penn Medicine Center for Evidence-based Practice (CEP) Video camera-assisted or electromagnetic placement of enteral feeding tubes
2022     Malaysian Health Technology Assessment (MaHTAS) Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma. NICE technology appraisal guidance 837
2022     National Institute for Health and Care Excellence (NICE) myCOPD for managing chronic obstructive pulmonary disease. NICE medical technologies guidance 68
2022     NIHR Health Technology Assessment programme Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial
2022     Penn Medicine Center for Evidence-based Practice (CEP) Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2022     Health Technology Wales (HTW) Left atrial appendage occlusion in patients with atrial fibrillation
2022     National Institute for Health and Care Excellence (NICE) Slow-release potassium bicarbonate-potassium citrate for treating distal renal tubular acidosis (terminated appraisal). NICE technology appraisal guidance 838
2022     National Institute for Health and Care Excellence (NICE) UroShield for preventing catheter-associated urinary tract infections. NICE medical technologies guidance 69
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022     Health Technology Wales (HTW) Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal). NICE technology appraisal guidance 839
2022     National Institute for Health and Care Excellence (NICE) Prontosan for treating acute and chronic wounds. NICE medical technologies guidance 67
2022     NIHR Health Technology Assessment programme Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2022     The Regional Health Technology Assessment Centre (HTA-centrum) Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies
2022     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal). NICE technology appraisal guidance 840